Literature DB >> 20426702

Current role of beta-blockers in the treatment of hypertension.

Wilbert S Aronow1.   

Abstract

IMPORTANCE OF THE FIELD: It is important to know which patients with hypertension will benefit from beta-blocker therapy and which beta-blockers should be used in the treatment of hypertension to reduce cardiovascular events and mortality. AREAS COVERED IN THIS REVIEW: Studies between 1981 and 2009 using a Medline search are reported. Beta-blockers should be used to treat hypertension in patients with previous myocardial infarction, acute coronary syndromes, angina pectoris, congestive heart failure, ventricular arrhythmias, supraventricular tachyarrhythmias, diabetes mellitus, after coronary artery bypass graft surgery, and in patients who are pregnant, have thyrotoxicosis, glaucoma, migraine, essential tremor, perioperative hypertension, or an excessive blood pressure response after exercise. WHAT THE READER WILL GAIN: The use of beta-blockers as first-line therapy in patients with primary hypertension has been controversial. However, the 2009 guidelines of the European Society of Hypertension state that large-scale meta-analyses of available data confirm that diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers do not significantly differ in their ability to lower blood pressure and to exert cardiovascular protection both in elderly and in younger patients. TAKE HOME MESSAGE: The key message of this paper is that atenolol should not be used as an antihypertensive drug and that the degree of reduction of mortality, myocardial infarction, stroke and congestive heart failure by antihypertensive therapy is dependent on the degree of lowering of aortic blood pressure. Newer vasodilator beta-blockers such as carvedilol and nebivolol may be more effective in reducing cardiovascular events than traditional beta-blockers, but this needs to be investigated by controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20426702     DOI: 10.1517/14656566.2010.482561

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  21 in total

1.  Antihypertensive drug therapy.

Authors:  Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2018-04

Review 2.  Managing Hypertension in the Elderly: What is Different, What is the Same?

Authors:  Wilbert S Aronow
Journal:  Curr Hypertens Rep       Date:  2017-08       Impact factor: 5.369

3.  Clinical significance of β2-adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma.

Authors:  Kengo Takahashi; Kyoichi Kaira; Akira Shimizu; Taisuke Sato; Norifumi Takahashi; Hiroomi Ogawa; Daisuke Yoshinari; Takehiko Yokobori; Takayuki Asao; Izumi Takeyoshi; Tetsunari Oyama
Journal:  Tumour Biol       Date:  2016-08-03

4.  A Novel function of Nebivolol: Stimulation of Adipose-derived Stem Cell Proliferation and Inhibition of Differentiation.

Authors:  Dong Lin; Joana E Ochoa; Zahra Barabadi; Andreas B Pfnur; Stephen E Braun; Reza Izadpanah; Eckhard Alt
Journal:  J Stem Cells Regen Med       Date:  2020-05-27

Review 5.  Contemporary Drug Treatment of Hypertension: Focus on Recent Guidelines.

Authors:  Wilbert S Aronow; William H Frishman
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

6.  Treatment of systemic hypertension.

Authors:  Wilbert S Aronow
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

Review 7.  Approaches for the Management of Resistant Hypertension in 2020.

Authors:  Wilbert S Aronow
Journal:  Curr Hypertens Rep       Date:  2020-01-08       Impact factor: 5.369

Review 8.  Managing Hypertension in Patients Aged 75 Years and Older.

Authors:  Yogita Rochlani; Mohammed Hasan Khan; Wilbert S Aronow
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

9.  Blood Pressure Goals and Targets in the Elderly.

Authors:  Wilbert S Aronow
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-07

10.  Prognostic significance of β2-adrenergic receptor expression in malignant melanoma.

Authors:  Akira Shimizu; Kyoichi Kaira; Keita Mori; Madoka Kato; Kimihiro Shimizu; Masahito Yasuda; Ayumi Takahashi; Tetsunari Oyama; Takayuki Asao; Osamu Ishikawa
Journal:  Tumour Biol       Date:  2015-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.